Biomarker Discovery is a process in which molecular substances in the body are used to indicate health or disease. One of the biggest challenges in biomarker discovery is the difficulty of identifying medium to low abundance proteins in complex biological samples.
We describe a mass spectrometry (MS) analytical platform resulting from the novel integration of acoustic droplet ejection (ADE) technology, an open-port interface (OPI), and electrospray io...
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with poor outcome. It is expected to be the leading cause of cancer-related death in 2030. The unique microe...
The majority of patients with advanced NSCLC do not respond to monotherapy with PD-1 axis inhibition, and more robust predictive biomarkers are needed. In this study, we assessed tumor sampl...
The GeoMx Digital Spatial Profiling technology enables high-plex RNA and protein profiling of any region within any tissue type. This workshop will highlight the latest developments toward e...
B-cell lymphomas and leukemias originate from the malignant transformation and proliferation of one or a small number of B cells. Since each B-cell expresses distinct B-cell receptors (BCRs)...
B-cell lymphomas and leukemias originate from the malignant transformation and proliferation of one or a small number of B cells. Since each B-cell expresses distinct B-cell receptors (BCRs)...
The prevalence of EGFR mutation rate positivity in NSCLC is high in Asia, and this is the case in Malaysia as well. This presentation will provide Malaysia’s approach in implementation...
NSCLC in Asia has high prevalence of EGFR Mutation and this is the case in Malaysia as well. This presentation will provide Malaysia’s approach in implementation of NGS in their 1st li...
DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
DATE: April 16, 2020 TIME: 9:00am PT, 12:00pm ET There is an increasing need to evaluate and understand unique phenotypes and mechanisms of action within the tumor microenvironment. Existing...
DATE: April 9, 2020 TIME: 8:00am PT, 11:00am ET Mass spectrometry-based proteomics allows the simultaneous measurement of a large number of proteins...
DATE: March 31, 2020 TIME: 7:00am PT, 10:00am PT Please join us for this webinar, during which we will present and discuss the promotion of NK cell-driven tumor immunity. In addition, we wil...
Whether you are performing killing assays, characterizing the tumor microenvironment, or investigating immunogenicity, primary cells are essential for the discovery of new therapeutics. Conc...
Digital spatial profiling (DSP) on the NanoString GeoMx platform enables high plex molecular profiling of clinical tissue samples. This new profiling strategy enables deep insights into the...
QIAGEN CLC Genomics Workbench is a powerful solution to analyze and visualize next generation sequencing (NGS) data. Powered by cutting-edge technology and accelerated algorithms, it support...
CRISPR revolutionized gene editing, but multi-target screening remains a complex goal. In addition, the fast pace of CRISPR technology development has brought sophisticated options for libra...
Recent advances in DNA sequencing and omics-based capabilities are revealing incredible therapeutic opportunities and quickly transforming drug discovery. Molecularly targeted drugs aim to e...
With an increasing push to improve safety, efficacy, and efficiency throughout the drug development pipeline, researchers are evermore looking to improve the predictive capacity of their in...
“The poor translatability of early-stage preclinical models is a major setback in oncology drug development. Immortalized cell lines, that are extensively used in drug screens, undergo...
Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in developed countries, and it affects over 25% of the population worldwide. Within the next five y...
The use of primary cells in vitro is compromised by the limited quantity of cells that can be isolated from one donor, a lack of or very restricted proliferation capacity (e.g. hepatocytes)...
We describe a mass spectrometry (MS) analytical platform resulting from the novel integration of acoustic droplet ejection (ADE) technology, an open-port interface (OPI), and electrospray io...
Pancreatic Ductal Adenocarcinoma (PDAC) is a highly aggressive disease associated with poor outcome. It is expected to be the leading cause of cancer-related death in 2030. The unique microe...
The majority of patients with advanced NSCLC do not respond to monotherapy with PD-1 axis inhibition, and more robust predictive biomarkers are needed. In this study, we assessed tumor sampl...
The GeoMx Digital Spatial Profiling technology enables high-plex RNA and protein profiling of any region within any tissue type. This workshop will highlight the latest developments toward e...
B-cell lymphomas and leukemias originate from the malignant transformation and proliferation of one or a small number of B cells. Since each B-cell expresses distinct B-cell receptors (BCRs)...
B-cell lymphomas and leukemias originate from the malignant transformation and proliferation of one or a small number of B cells. Since each B-cell expresses distinct B-cell receptors (BCRs)...
The prevalence of EGFR mutation rate positivity in NSCLC is high in Asia, and this is the case in Malaysia as well. This presentation will provide Malaysia’s approach in implementation...
NSCLC in Asia has high prevalence of EGFR Mutation and this is the case in Malaysia as well. This presentation will provide Malaysia’s approach in implementation of NGS in their 1st li...
DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
DATE: April 16, 2020 TIME: 9:00am PT, 12:00pm ET There is an increasing need to evaluate and understand unique phenotypes and mechanisms of action within the tumor microenvironment. Existing...
DATE: April 9, 2020 TIME: 8:00am PT, 11:00am ET Mass spectrometry-based proteomics allows the simultaneous measurement of a large number of proteins...
DATE: March 31, 2020 TIME: 7:00am PT, 10:00am PT Please join us for this webinar, during which we will present and discuss the promotion of NK cell-driven tumor immunity. In addition, we wil...
Whether you are performing killing assays, characterizing the tumor microenvironment, or investigating immunogenicity, primary cells are essential for the discovery of new therapeutics. Conc...
Digital spatial profiling (DSP) on the NanoString GeoMx platform enables high plex molecular profiling of clinical tissue samples. This new profiling strategy enables deep insights into the...
QIAGEN CLC Genomics Workbench is a powerful solution to analyze and visualize next generation sequencing (NGS) data. Powered by cutting-edge technology and accelerated algorithms, it support...
CRISPR revolutionized gene editing, but multi-target screening remains a complex goal. In addition, the fast pace of CRISPR technology development has brought sophisticated options for libra...
Recent advances in DNA sequencing and omics-based capabilities are revealing incredible therapeutic opportunities and quickly transforming drug discovery. Molecularly targeted drugs aim to e...
With an increasing push to improve safety, efficacy, and efficiency throughout the drug development pipeline, researchers are evermore looking to improve the predictive capacity of their in...
“The poor translatability of early-stage preclinical models is a major setback in oncology drug development. Immortalized cell lines, that are extensively used in drug screens, undergo...
Non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in developed countries, and it affects over 25% of the population worldwide. Within the next five y...
The use of primary cells in vitro is compromised by the limited quantity of cells that can be isolated from one donor, a lack of or very restricted proliferation capacity (e.g. hepatocytes)...
Follow
